Why Estrogen Matters: What the Data Says About Menopause and Long-Term Health
Estrogen affects more than hot flashes. Learn how
menopause relates to bones, heart health, frozen shoulder, dry eyes and long-term wellness.
Why Estrogen Matters: Menopause and Long-Term Health
When people hear "estrogen," they often think of hot flashes, night sweats, and vaginal dryness. Those symptoms matter. But estrogen also plays a role in tissues throughout the body - including bone, blood vessels, pelvic tissues, connective tissue, eyes, and skin. That is why the menopause conversation is changing. We are moving away from fear-based, one-size-fits-all rules and toward personalized conversations about what estrogen does and who may benefit.
Estrogen is not a magic anti-aging treatment, and it is not right for everyone. But it is also not "just a reproductive hormone." For many women, losing estrogen affects comfort, mobility, and long-term health in ways that go far beyond hot flashes.
Localized vs. systemic estrogen
Before talking about benefits, it is important to separate localized vaginal estrogen from systemic estrogen. Localized estrogen is used in or around the vagina and vulva as a cream, tablet, insert, or ring. It is often used for genitourinary syndrome of menopause, which can include vaginal dryness, burning, pain with sex, urinary urgency, and recurrent urinary tract infections. Low-dose localized estrogen works mainly in local tissues and has very little systemic absorption for most patients.
Systemic estrogen travels through the bloodstream and can affect the whole body. It may be delivered as a patch, gel, spray, or pill. Systemic estrogen is the type discussed when we talk about hot flashes, sleep disruption, bone protection, and broader body effects. The risks and benefits are different from localized therapy, so they should not be treated as the same medication.
Bones, joints, and frozen shoulder
Estrogen helps regulate bone turnover. When estrogen levels fall in menopause, bone breakdown can speed up, increasing the risk of osteopenia, osteoporosis, and fractures. This is one of the strongest evidence-based benefits of systemic estrogen: hormone therapy has been shown to prevent bone loss and reduce fracture risk in appropriate candidates.
More recently, researchers have been discussing the "musculoskeletal syndrome of menopause." This includes joint pain, loss of muscle mass, tendon changes, reduced flexibility, and conditions like adhesive capsulitis, better known as frozen shoulder. Frozen shoulder can cause severe pain and limited shoulder movement, making everyday tasks difficult.
A 2023 retrospective study found that postmenopausal women using hormone therapy had lower rates of adhesive capsulitis than those not using hormone therapy. This does not mean estrogen is a guaranteed treatment for frozen shoulder, but it supports what many women report: menopause can affect how the body moves, heals, and tolerates activity.
Heart health and timing
Heart health is one of the most important parts of the estrogen conversation. Cardiovascular disease risk rises as women age, and the menopause transition is a critical time to assess blood pressure, cholesterol, insulin resistance, family history, inflammation, and lifestyle risk factors.
The relationship between estrogen and heart health is nuanced. Hormone therapy is not prescribed as a blanket "heart disease prevention" plan for every woman. However, modern data shows that timing matters. A healthy 52-year-old who recently reached menopause is not the same as a 72-year-old starting therapy for the first time. The Menopause Society recommends risk stratification by age and time since menopause, and newer labeling discussions have moved toward more individualized risk-benefit conversations.
Route matters too. Transdermal estrogen, such as a patch, bypasses the liver first-pass effect and may lower the risk of blood clots and stroke compared with oral estrogen in some patients. This is why a thoughtful estrogen conversation should include personal risk factors, route, dose, and follow-up.
Dry eyes, skin, and connective tissue
Dry eyes are one of the less-discussed symptoms of the menopause transition. Hormonal changes can affect the ocular surface, tear film, oil glands, and inflammation. Some women notice gritty, burning, watery, or irritated eyes during perimenopause or menopause.
The data around systemic hormone therapy and dry eye is mixed, so estrogen should not be presented as a simple "dry eye cure." Still, dry eyes are worth discussing because they may be part of a bigger pattern of tissue changes during midlife. Women with persistent symptoms should be evaluated by an eye care professional, especially if they have pain, vision changes, autoimmune disease, or contact lens intolerance.
Estrogen also affects skin, collagen, and connective tissue. Many women notice changes in skin dryness, elasticity, vulvar tissue comfort, and sexual function as estrogen declines. Localized estrogen can be especially helpful for vulvovaginal and urinary symptoms because it directly supports the tissue most affected.
Longevity: not magic, but meaningful
The word "longevity" can be misleading if it sounds like a promise to live longer. Estrogen is not a guarantee of a longer life, and hormone therapy should not be sold as an anti-aging shortcut. But long-term health is also about healthspan - staying mobile, sleeping well, maintaining bone strength, preserving sexual and urinary comfort, and reducing preventable suffering
Long-term Women's Health Initiative follow-up found that menopausal hormone therapy was not associated with an increase in all-cause mortality after 18 years of follow-up. Other analyses suggest potential mortality and cardiovascular benefit when therapy is started in younger women or closer to menopause, but this depends on patient selection and the type of therapy used. The takeaway is not "everyone needs estrogen." The takeaway is that estrogen deserves an individualized, evidence-based discussion.
The bottom line
Estrogen matters because menopause affects the whole body. Hot flashes and night sweats may be the loudest symptoms, but they are not the only ones. Bone loss, joint pain, frozen shoulder, vaginal and urinary symptoms, sleep disruption, dry eyes, sexual discomfort, and cardiovascular risk all deserve attention.
At Arcadia Women's Wellness, Julia Cyr, DNP, and Kristina Calligan, FNP, as Menopause Society Certified Practitioners, help women understand their options with clarity and nuance. We believe estrogen therapy should not be approached with fear or hype. It should be approached with education, thoughtful screening, shared decision-making, and a plan personalized to your body and goals. You can schedule an appointment with Arcadia Women’s Wellness here.
Medical disclaimer: This article is for education only and does not replace individualized medical advice.
Sources
The Menopause Society 2022 Hormone Therapy Position Statement: Used for individualized risk-benefit framing, age/timing stratification, vaginal estrogen duration, and bone loss/fracture prevention. https://menopause.org/wp-content/uploads/press-release/ht-position-statement-release.pdf
The Menopause Society comments on FDA hormone therapy announcement, 2025: Used for distinction between low-dose vaginal estrogen and systemic estrogen risks. https://menopause.org/press-releases/the-menopause-society-comments-on-the-fda-announcement-on-hormone-therapy
FDA request for labeling changes related to menopausal hormone therapies, 2026: Used for updated labeling/risk-benefit context. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations
Saltzman et al., 2023, Orthopaedic Journal of Sports Medicine/PMC: Used for adhesive capsulitis/frozen shoulder and HRT association. https://pmc.ncbi.nlm.nih.gov/articles/PMC10392282/
Wright et al., 2024, Climacteric/PubMed: Used for musculoskeletal syndrome of menopause framing. https://pubmed.ncbi.nlm.nih.gov/39077777/
Bhupathiraju et al., 2018, Nurses' Health Study/PMC: Used for vaginal estrogen and chronic disease risk context. https://pmc.ncbi.nlm.nih.gov/articles/PMC6538478/
Vallibhakara et al., 2025, Maturitas/ScienceDirect: Used for dry eye symptom prevalence in midlife women. https://www.sciencedirect.com/science/article/pii/S037851222500502X
Manson et al., 2017, JAMA: Used for Women's Health Initiative long-term all-cause mortality framing. https://jamanetwork.com/journals/jama/fullarticle/2653735
Hodis and Mack, 2022, Cancer Journal/PMC: Used for timing hypothesis, CVD/all-cause mortality discussion and nuance. https://pmc.ncbi.nlm.nih.gov/articles/PMC9178928/
Estrogen Matters by Avrum Bluming, MD, and Carol Tavris, PhD; Mary Claire Haver, MD discussion: Used as broader educational context for the blog series; clinical statements should be verified against primary literature. https://estrogenmatters.com/; https://thepauselife.com/blogs/the-unpaused-podcast/the-truth-about-estrogen-what-the-womens-health-initiative-got-wrong-with-dr-avrum-bluming-dr-carol-tavris